Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of KPV and Vilon — mechanism, dosing, side effects, legal status, and pricing.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH residues 11-13), the smallest alpha-MSH fragment retaining anti-inflammatory activity. Research-only; not FDA-approved. Evidence is primarily preclinical with no controlled human trials.
Vilon is a synthetic dipeptide (Lys-Glu / KE) from the Khavinson bioregulator series, originally derived from thymus extracts and studied in Russian preclinical models as an immunomodulator and geroprotector. Not FDA-approved; all published evidence originates from a single research group.
KPV
Vilon
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
KPV
Vilon
COA corpus from Disclosed Labs — independently tested batches only.
KPV
89
COAs
99.5%
Avg purity
15
Labs
Vilon
11
COAs
99.7%
Avg purity
6
Labs
Dalmasso et al. (Gastroenterology 2008; PMID 18061177) demonstrated PepT1-mediated uptake of KPV and reduction of DSS- and TNBS-induced colitis in mice. Kannengiesser et al. (Inflammatory Bowel Diseases 2008; PMID 18092346) showed anti-inflammatory effects in two murine colitis models at least partly independent of MC1R signaling. Brzoska et al. (Endocrine Reviews 2008; PMID 18612139) reviewed alpha-MSH and related tripeptides, summarizing NF-kB suppression across cell types. Subsequent preclinical work (largely from the Merlin group at Georgia State) has explored oral nanoparticle and polysaccharide-hydrogel delivery for IBD. No controlled human trials have been published.
Key references
Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.
KPV and Vilon are both in the Immune category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs